Molecular Partners Reports Q3 2026 Financial Results, Deepens Radiotherapy Focus
The company said dosing is ongoing in the fully recruited dose level 2 of its MP0712 Phase 1/2a study; initial safety data is expected to be
Related stories
Al Baha Reports Q3 Net Profit of SAR 2.7 Million
M impact | EQUITY | Oct 29, 2026, 03:02 PM UTC
Shell Posts Highest Quarterly Profit Since 2022, Raises Buyback
Shell reported third-quarter net profit of $10.81 billion, above analysts’ average estimate of $10.33 billion. Record refining margins and stronger LNG performance helped the resul
M impact | EQUITY | Oct 29, 2026, 03:01 PM UTC
Alphabet Shares Plunge More Than 10% After Earnings
Alphabet shares fell more than 10% Thursday morning, putting ETFs with large holdings in the company under pressure after its latest earnings report.
M impact | EQUITY | Oct 29, 2026, 03:01 PM UTC
USD.AI Closes $106 Million Facility for NexGen Cloud
USD.AI closed a $106 million senior secured loan facility for NexGen Cloud on 29 October 2026, alongside lenders Silver Point Capital and Victory Park Capital through GLX. The faci
M impact | EQUITY | Oct 29, 2026, 03:01 PM UTC
FIIs Sell ₹943.60 Crore of Indian Equities as Sensex Jumps 905 Points
Provisional exchange data showed domestic institutional investors bought ₹1,924.41 crore of equities on Thursday.
M impact | EQUITY | Oct 29, 2026, 03:01 PM UTC
Corning Reports Third-Quarter 2026 Revenue of $4.86 Billion
Revenue rose 18.4% year over year, net income increased 58.1% to $680 million, and diluted EPS rose to $0.78 from $0.50.
M impact | EQUITY | Oct 29, 2026, 03:01 PM UTC